Opthea Ltd. ADR (OPT): Price and Financial Metrics
GET POWR RATINGS... FREE!
OPT Stock Summary
- Of note is the ratio of Opthea Ltd's sales and general administrative expense to its total operating expenses; merely 0.4% of US stocks have a lower such ratio.
- For OPT, its debt to operating expenses ratio is greater than that reported by merely 0.47% of US equities we're observing.
- Revenue growth over the past 12 months for Opthea Ltd comes in at -316.96%, a number that bests only 0.17% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Opthea Ltd, a group of peers worth examining would be HGEN, GOVX, ZYME, NVAX, and IMMP.
- To dig deeper into the stock's financial statements, go to OPT's page on browse-edgar?action=getcompany&CIK=0001815620.
OPT Stock Price Chart Interactive Chart >
OPT Price/Volume Stats
|Current price||$7.35||52-week high||$16.23|
|Prev. close||$7.05||52-week low||$4.73|
|Day high||$7.35||Avg. volume||5,231|
|50-day MA||$6.20||Dividend yield||N/A|
|200-day MA||$6.89||Market Cap||323.34M|
Opthea Ltd. ADR (OPT) Company Bio
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.
Most Popular Stories View All
OPT Latest News Stream
|Loading, please wait...|
OPT Latest Social Stream
View Full OPT Social Stream
Latest OPT News From Around the Web
Below are the latest news stories about Opthea Ltd that investors may wish to consider to help them evaluate OPT as an investment opportunity.
Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The data presented was a prespecified subgroup analysis of a Phase 2b dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD). Sixty-six participants (18%) with Polypoidal Choroidal Vasculopathy (PCV) out of a total stud
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab alone +6.7 letters comparative superiority of 2 mg OPT-302 combination therapy (p = 0.0253) in patients with PCV – a subtype of AMD, prevalent among Asian populations with high unmet medical need MELBOURNE, Australia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Opthea L
MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. The presentation will be available beginning Thursday, February 1
MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022. Professor Gemmy Cheung will present data from patients with polypoidal choroidal vasculo
MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it has received a A$6.6 million (US$4.9 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2020/2021 financial year, and represents the amount di
OPT Price Returns